ARTICLE | Finance
Prenatal and beyond
Why Sofinnova led $55.5M F round for molecular diagnostics play Natera
April 20, 2015 7:00 AM UTC
Natera Inc. is keeping mum on its financing plans, but the commercial-stage molecular diagnostics company is the latest in a string of life sciences companies raising venture rounds beyond series D from a syndicate including crossover investors. Many have now gone public or are in the IPO queue.
Earlier this month, Natera raised $55.5 million in a series F round led by new investor Sofinnova Ventures. Capital Research and Management; Franklin Templeton Investments; Jennison Associates; RA Capital; Healthcor Partners; and OrbiMed Advisors participated...